Showing results (61-70 of 73) with videos related to
Sort By:
Pageof 8
The Journal of Headache and Pain|March 23, 2023
Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 studyPiero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.Neuroscience Letters|March 22, 2008
Analysis of LGI1 promoter sequence, PDYN and GABBR1 polymorphisms in sporadic and familial lateral temporal lobe epilepsyGiorgia Bovo, Erica Diani, Francesca Bisulli, et al.Epilepsy Research|February 22, 2011
Association of intronic variants of the KCNAB1 gene with lateral temporal epilepsyGiorgia Busolin, Sandro Malacrida, Francesca Bisulli, et al.Journal of Neurology|January 17, 2024
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational studyPiero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.Neurology and Therapy|March 7, 2024
Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 StudyPiero Barbanti, Gabriella Egeo, Stefania Proietti, et al.Epilepsia|April 30, 2013
Low penetrance of autosomal dominant lateral temporal epilepsy in Italian families without LGI1 mutationsRoberto Michelucci, Elena Pasini, Sandro Malacrida, et al.Neurology and Therapy|June 9, 2026
Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III StudyPiero Barbanti, Cinzia Aurilia, Massimo Filippi, et al.The Journal of Headache and Pain|March 20, 2022
Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen studyRaffaele Ornello, Carlo Baraldi, Simona Guerzoni, et al.Journal of Neurology|May 7, 2025
A 24-week prospective, multicenter, real-world study on eptinezumab's effectiveness and safety in migraine prevention (EMBRACE II)Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.The Journal of Headache and Pain|October 2, 2025
Profiling the real-world migraine patient: public health insights from sociodemographic, lifestyle, and clinical data in the Italian National Migraine Registry (I-GRAINE)Piero Barbanti, Giulia Fiorentini, Cecilia Camarda, et al.Pageof 8